Corcept Therapeutics | CORT - Pre Tax Profit


Corcept Therapeutics reported $15.24M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Alaunos Therapeutics USD -7.84M 633K Dec/2023
ANI Pharmaceuticals USD 49.52M 39M Sep/2025
Ardelyx USD -400K 467K Dec/2025
Assertio Holdings USD -2.88M 648K Sep/2024
Aurora Cannabis CAD -1.58M 48.55M Dec/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Canopy Growth CAD -62.26M 60.84M Dec/2025
Corcept Therapeutics USD 15.24M 16.45M Sep/2025
Eli Lilly USD 7.23B 456M Sep/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
J&J USD 4.97B 2.53B Dec/2025
Knight Therapeutics CAD -1.92M 13.69M Sep/2025
Lexicon Pharmaceuticals USD -12.77M 16.02M Sep/2025
Merck USD 6.74B 22M Sep/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Novartis USD 4.64B 445M Dec/2025
Novartis USD 5.17B 637M Sep/2025
Omeros USD -65.12M 21.27M Jun/2024
Pacira USD 9.52M 11.45M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
Supernus Pharmaceuticals USD -1.91M 56.04M Dec/2025
TG Therapeutics USD 45.09M 19.18M Dec/2025